Science & Innovation
Our Platforms
Molecular Glue Degrader
Molecular Glue Target Discovery Platform
AI-Driven Molecular Glue Rational Design Platform
Pipeline
Leveraging its proprietary Glue Degrader Discovery(GDD©) technology platform, GluBio is advancing a diverse pipeline of highly selective novel molecular glue degraders (MGDs) targeting key disease-relevant proteins across multiple therapeutic areas. Currently, the company has three clinical-stage programs (GLB-001 and GLB-002) and several preclinical candidates, all aimed at addressing unmet medical needs in oncology, autoimmune diseases, and genetic disorders.
Clinical Trials
GluBio is currently conducting three clinical trials for hematologic malignancies
in both China and the United States.
Status
Recruiting
Clinical Trial Title
A First-in-human, Phase 1, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Phase
Phase I
Location
United States
Age/Gender
>=18 years
Male & Female
Male & Female
Indications
Acute Myeloid Leukemia, Higher-risk Myelodysplastic Syndromes
Status
Recruiting
Clinical Trial Title
A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients with Myeloid Malignancies
Phase
Phase I
Location
China
Age/Gender
>=18 years
Male & Female
Male & Female
Indications
Myeloid Malignancy, including Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes, Acute Myeloid Leukemia, etc.
Status
Active, not recruiting
Clinical Trial Title
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of GLB-002 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL)
Phase
Phase I
Location
China
Age/Gender
>=18 years
Male & Female
Male & Female
Indications
Non-Hodgkin Lymphoma, including Follicular Lymphoma, Large B-cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Peripheral T-cell Lymphoma, Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia, etc.
Collaboration
External partnerships are a key strategy for expanding GluBio's R&D pipeline and accelerating its progress in clinical and commercial development.